Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
2004 1
2010 3
2013 1
2016 2
2017 3
2018 1
2019 2
2020 1
2021 2
2022 4
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Vertebrate-class-specific binding modes of the alphavirus receptor MXRA8.
Zimmerman O, Zimmerman MI, Raju S, Nelson CA, Errico JM, Madden EA, Holmes AC, Hassan AO, VanBlargan LA, Kim AS, Adams LJ, Basore K, Whitener BM, Palakurty S, Davis-Adams HG, Sun C, Gilliland T Jr, Earnest JT, Ma H, Ebel GD, Zmasek C, Scheuermann RH, Klimstra WB, Fremont DH, Diamond MS. Zimmerman O, et al. Cell. 2023 Oct 26;186(22):4818-4833.e25. doi: 10.1016/j.cell.2023.09.007. Epub 2023 Oct 6. Cell. 2023. PMID: 37804831
Entry receptors - the gateway to alphavirus infection.
Zimmerman O, Holmes AC, Kafai NM, Adams LJ, Diamond MS. Zimmerman O, et al. J Clin Invest. 2023 Jan 17;133(2):e165307. doi: 10.1172/JCI165307. J Clin Invest. 2023. PMID: 36647825 Free PMC article. Review.
Ex vivo effect of JAK inhibition on JAK-STAT1 pathway hyperactivation in patients with dominant-negative STAT3 mutations.
Lobo PB, Guisado-Hernández P, Villaoslada I, de Felipe B, Carreras C, Rodriguez H, Carazo-Gallego B, Méndez-Echevarria A, Lucena JM, Aljaro PO, Castro MJ, Noguera-Uclés JF, Milner JD, McCann K, Zimmerman O, Freeman AF, Lionakis MS, Holland SM, Neth O, Olbrich P. Lobo PB, et al. Among authors: zimmerman o. J Clin Immunol. 2022 Aug;42(6):1193-1204. doi: 10.1007/s10875-022-01273-x. Epub 2022 May 4. J Clin Immunol. 2022. PMID: 35507130 Free article.
Immunoglobulin replacement products protect against SARS-CoV-2 infection in vivo despite poor neutralizing activity.
Zimmerman O, Altman Doss AM, Ying B, Liang CY, Mackin SR, Davis-Adams HG, Adams LJ, VanBlargan LA, Chen RE, Scheaffer SM, Desai P, Raju S, Mantia TL, O'Shaughnessy CC, Monroy JM, Wedner HJ, Rigell CJ, Kau AL, Dy TB, Ren Z, Turner JS, O'Halloran JA, Presti RM, Kendall PL, Fremont DH, Ellebedy AH, Diamond MS. Zimmerman O, et al. JCI Insight. 2024 Feb 8;9(3):e176359. doi: 10.1172/jci.insight.176359. JCI Insight. 2024. PMID: 38175703 Free PMC article.
mRNA vaccine boosting enhances antibody responses against SARS-CoV-2 Omicron variant in individuals with antibody deficiency syndromes.
Zimmerman O, Altman Doss AM, Kaplonek P, Liang CY, VanBlargan LA, Chen RE, Monroy JM, Wedner HJ, Kulczycki A Jr, Mantia TL, O'Shaughnessy CC, Davis-Adams HG, Bertera HL, Adams LJ, Raju S, Zhao FR, Rigell CJ, Dy TB, Kau AL, Ren Z, Turner JS, O'Halloran JA, Presti RM, Fremont DH, Kendall PL, Ellebedy AH, Alter G, Diamond MS. Zimmerman O, et al. Cell Rep Med. 2022 Jun 21;3(6):100653. doi: 10.1016/j.xcrm.2022.100653. Epub 2022 Jun 9. Cell Rep Med. 2022. PMID: 35688161 Free PMC article.
SARS-CoV-2 booster vaccination rescues attenuated IgG1 memory B cell response in primary antibody deficiency patients.
Lin FJ, Doss AMA, Davis-Adams HG, Adams LJ, Hanson CH, VanBlargan LA, Liang CY, Chen RE, Monroy JM, Wedner HJ, Kulczycki A, Mantia TL, O'Shaughnessy CC, Raju S, Zhao FR, Rizzi E, Rigell CJ, Dy TB, Kau AL, Ren Z, Turner JS, O'Halloran JA, Presti RM, Fremont DH, Kendall PL, Ellebedy AH, Mudd PA, Diamond MS, Zimmerman O, Laidlaw BJ. Lin FJ, et al. Among authors: zimmerman o. Front Immunol. 2022 Dec 22;13:1033770. doi: 10.3389/fimmu.2022.1033770. eCollection 2022. Front Immunol. 2022. PMID: 36618402 Free PMC article.
Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease.
Zimmerman O, Rösler B, Zerbe CS, Rosen LB, Hsu AP, Uzel G, Freeman AF, Sampaio EP, Rosenzweig SD, Kuehn HS, Kim T, Brooks KM, Kumar P, Wang X, Netea MG, van de Veerdonk FL, Holland SM. Zimmerman O, et al. Open Forum Infect Dis. 2017 Sep 22;4(4):ofx202. doi: 10.1093/ofid/ofx202. eCollection 2017 Fall. Open Forum Infect Dis. 2017. PMID: 29226168 Free PMC article.
23 results